Tamoxifen as an anti-tumour agent: effect on oestrogen binding.
Tamoxifen (ICI 46,474) has been shown to possess anti-tumour properties in the dimethylbenz(a)anthracene (DMBA)-induced rat mammary carcinoma model. During tamoxifen therapy the binding of [3H]oestradiol in vivo to uterine (P less than 0-001), vaginal (P less than 0 X 01) and tumour (P less than 0-001) tissues was significantly reduced. Tamoxifen therapy was without effect on the binding of [3H]oestradiol in heart tissue. The determination of specific oestrogen-binding components in vitro was significantly reduced (P less than 0-01) in tumours from tamoxifen-treated rats and tamoxifen inhibited the binding of [3H]oestradiol to 8S oestrogen-binding components, derived from rat uteri and DMBA-induced tumours, in vitro.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D004958:Estradiol / Q000378:metabolism*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats; D011956:Receptors, Cell Surface; D013267:Stilbenes / Q000627:therapeutic use*; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use*; D014599:Uterus / Q000187:drug effects / Q000378:metabolism; D014621:Vagina / Q000187:drug effects / Q000378:metabolism
D011956:Receptors, Cell Surface; D013267:Stilbenes; D013629:Tamoxifen; D004958:Estradiol; D015127:9,10-Dimethyl-1,2-benzanthracene